Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Popular drugs for diabetes and Weight loss It could have an unexpected side effect.
The agonists of the 1 (LPG-1) peptide receptor similar to glucagon, which are used to treat diabetes and/or type 2 obesity, were linked to vision problems in a small study at the University of British Columbia.
Some common GLP-1 drugs Include Ozempic and Wegovy, which contain semaglutida as an active ingredient, and Mounjaro and Zepbound, which contain tirzepatida.
Weight loss can be helped drinking this, the study suggests
In the study, nine patients who used a LPG-1 developed “ophthalmic complications,” according to researchers. The average age of patients was 57.4 years, according to study findings.
The agonists of the 1 (LPG-1) peptide receptor similar to glucagon, which are used to treat diabetes and/or type 2 obesity, were linked to vision problems in a small study. (Istock)
Seven of the patients had an anterior non -arteritic ischemic optical neuropathy (Naion), which causes loss of vision in an eye.
A patient developed bilateral papillitis, which implies swollen optical nerves that can cause deteriorated vision, and another had acute paracentral maculopathy, which leads to a blind spot in the retina.
Ozempic’s health benefits continue to grow, but are it worth the risks?
All patients had a history of type 2 diabetes, hyperlipidemia (high or fat lipids), hypertension and/or sleep apnea.
The findings were published in Jama Ofthalmology.
“In one of the cases presented, the patient was taking the medications for weight loss and had no previous history of diabetes (which may also be linked to the condition)”, the main author, the author Mahyar Etminan, medical professor Associated at the University of the University of Columbia British told Fox News Digital.
A doctor (not in the photo) emphasized that these medications should only be taken under the care of a health professional and that “the good and consistent monitoring for dose adjustments with the monitoring of side effects” is essential. (Istock)
“In another case, when the drug stopped and reintroduced, the condition reappeared, strengthening a causal link.”
Ziyad Al-Aly, clinical epidemiologist at the University of Washington in St. Louis, did not participate in the study, but shared his comments on the findings.
“This is a very small study and was not controlled, which means that it did not include people who did not use GLP-1 drugs,” he told Fox News Digital.
“The history of LPG-1 is still being written, and we are learning something new about these drugs every day.”
“This makes it impossible to know if the informed eye problems are caused by these drugs.”
However, the doctor said: “The history of LPG-1 is still being written, and we are learning something new about these drugs every day. The findings in this study must be further further.”
Seven of the patients in the study developed anterior non -arteritic ischemic optical neuropathy (Naion), which causes loss of vision in an eye. (Istock)
Etminan, main author of the study, also recognized the limitations of the study.
“These data were derived from a series of individual cases and was not an epidemiological study,” he said. “However, another recent epidemiological study also confirmed an increase in risk.”
Al-Ali requested large and controlled studies, including people who take the medication and a control group of people who do not use the medication, to evaluate the long-term effects of these medications, including eye problems.
“Meanwhile, for people who may be at risk of vision problems, or who already have vision problems, caution is recommended,” he added. “People should do To determine if GLP-1 is the appropriate medication for them. “
“This is a very small study and was not controlled, which means that it did not include people who did not use GLP-1 drugs,” a doctor told Fox News Digital. (Istock)
Etminan echoed that warning guide.
“Those who take these diabetes medications should probably continue taking them for their cardiovascular benefitsBut take into account the signs of Naion, “he advised.
“The healthy people who lead them to lose some pounds for an event may want to weigh more careful the risks compared to the benefits of taking these medications.”
“Most of the side effects of the vision seem to solve when the medication stops.”
Dr. Seth Kipnis, medical director of Bariatric and Robotics Surgery at Hackensack Meridian Jersey Shore University Medical Center, said there have been “rare and unusual side effects” of this kind of medicines, but believes that the Vision changes It seems more related to rapid blood sugar changes caused by medications than with medications themselves.
Click here to get the Fox News application
“We have encouraged any patient who is in this type of medicines to inform any unusual symptoms to their Prescribing doctors“Kipnis, who didn’t participate in the investigation, told Fox News Digital.
“Most of the side effects of the vision seem to solve when the medication stops.”
Click here to register in our health newsletter
Kipnis emphasized that these medications should only be taken under the care of a health professional and that “the good and consistent monitoring for dose adjustments with the monitoring of side effects” is fundamental.
When he was contacted by Fox News Digital, Novo Nordisk (Ozempic and Wegovy manufacturer) provided the following statement.
“Those who take these diabetes medications should probably continue taking them for their cardiovascular benefits, but take into account the signs of Naion,” said a doctor. (Istock)
“Naion is a very rare ocular disease, and it is not an adverse drug reaction for marketed semaglutidal formulations (Ozempic®, Rybelsus® and Wegovy®) according to approved labels. After an exhaustive evaluation of studies of the University of Southern The internal security evaluation of Denmark and Novo Nordisk, Novo Nordisk, believe that the risk profile of the semagglutida is still unchanged. “
The company also pointed out that ocular conditions are “well -known comorbidities” for people. Living with diabetes.
For more health articles, visit www.foxnews.com/health
“Any decision to start treatment with medications only with recipe should be done in consultation with a health professional who must carry out a risk assessment for the patient in question, weighing the benefits of treatment with potential risks,” said Novo Nordisk.
